Freeline Therapeutics Holdings Plc (FRLN) Key Ratios
$6.48
$0.00 (0.00%)As on 29-Feb-2024 09:30EDT
Market cap
$28 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -99.19 | -- | -- | -- | -- |
| EBIT | 38.93 | 49.19 | 35.21 | -23.19 | -236.20 |
| Net Profit | 24.50 | 18.83 | 26.40 | -29.55 | -- |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -15,955.75 | -15,955.75 | -11,456.11 | -15,955.75 | -- |
| Net Margin
| -- | -- | -11,912.70 | -- | -- |
| Return on equity
| -78.78 | -96.22 | -179.73 | -102.94 | -75.84 |
| Return on Capital
| -77.64 | -124.52 | -- | -99.53 | -75.84 |
| Return on Assets
| -66.43 | -77.22 | -78.33 | -78.13 | -68.53 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.11 | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
-99.53
|
-75.84
|
-57.55
|
-99.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-179.73
Lower than Peers by 139.44
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-179.73
|
-102.94
|
-75.84
|
-57.55
|
-99.90
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-78.33
Lower than Peers by 47.50
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-78.33
|
-78.13
|
-68.53
|
-52.63
|
-83.24
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
-11,456.11
Lower than Peers by 11,373.90
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-11,456.11
|
-15,955.75
|
--
|
--
|
--
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
-11,912.70
Lower than Peers by 11,822.82
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-11,912.70
|
-14,420.10
|
--
|
--
|
--
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.01
Lower than Peers by 0.01
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-0.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
EBIT Growth
35.21
Higher than Peers by 36.16
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
35.21
|
30.86
|
-38.98
|
-60.97
|
-92.25
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
26.40
Higher than Peers by 33.58
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
26.40
|
36.63
|
-45.75
|
-78.68
|
-61.97
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
0.11
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.08
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
0.08
|
0.05
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.95
Lower than Peers by 3.86
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
1.95
|
2.18
|
6.20
|
13.72
|
7.16
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
1.90
Lower than Peers by 3.79
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
1.90
|
1.61
|
5.89
|
13.56
|
7.09
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
-4.76
Lower than Peers by 2.67
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-4.76
|
-9.55
|
-31.49
|
-11.37
|
-88.52
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
453.86
Higher than Peers by 434.88
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
453.86
|
199.35
|
--
|
--
|
--
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
0.01
|
0.01
|
--
|
--
|
--
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
1,018.50
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
2,525.58
|
725.85
|
371.52
|
172.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
1,600.14
|
1,014.87
|
1,317.67
|
878.18
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
1,943.94
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.95
Lower than Peers by 4.40
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
0.95
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.05
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
-0.05
|
0.43
|
0.88
|
2.70
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
28
Lower than Peers by 119
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
28
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|